Shin Poong Pharm.Co.,Ltd.

KSE 019170.KS

Shin Poong Pharm.Co.,Ltd. EBITDA Margin for the year ending December 31, 2023: -19.88%

Shin Poong Pharm.Co.,Ltd. EBITDA Margin is -19.88% for the year ending December 31, 2023, a -87.26% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Shin Poong Pharm.Co.,Ltd. EBITDA Margin for the year ending December 31, 2022 was -10.62%, a -1,676.33% change year over year.
Shin Poong Pharm.Co.,Ltd. EBITDA Margin for the year ending December 31, 2021 was 0.67%, a -93.67% change year over year.
Shin Poong Pharm.Co.,Ltd. EBITDA Margin for the year ending December 31, 2020 was 10.64%, a -11.73% change year over year.
Shin Poong Pharm.Co.,Ltd. EBITDA Margin for the year ending December 31, 2019 was 12.05%, a 18.15% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KSE: 019170.KS

Shin Poong Pharm.Co.,Ltd.

CEO	Mr. Jei-Man Ryu
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	161, Yeoksam-ro
Employees	828
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years